The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company announced it has resubmitted its New Drug Application (NDA) to the U.S. FDA for TLX101-Px (Pixclara®), a brain cancer imaging candidate. Telix's resubmission includes new data addressing the FDA's previous requests and could bring the first FDA-approved targeted PET agent for adult and paediatric brain cancer imaging to the U.S. market.
Image source: Getty Images
What did Telix Pharmaceuticals report?
- Resubmitted NDA for TLX101-Px (Pixclara®) brain cancer imaging agent to U.S. FDA
- Submission includes additional data and statistical analysis to address FDA's Complete Response Letter
- TLX101-Px has Orphan Drug and Fast Track designations from the FDA
- No FDA‑approved targeted amino acid PET agent currently available for brain cancer imaging in the U.S.
- TLX101-Px is intended for both adult and paediatric glioma imaging
What else do investors need to know?
TLX101-Px is being developed to help doctors distinguish between recurrent or progressing glioma and changes caused by prior treatments. This could make a real difference for patients struggling with brain cancer by helping their clinical teams make better informed decisions.
Globally, PET imaging with 18F-FET (the basis for TLX101-Px) is part of clinical guidelines, but no similar FDA-approved product exists in the U.S. The agent targets LAT1 and LAT2 transport proteins and also has potential as a companion diagnostic for Telix's investigational brain cancer therapy, TLX101-Tx.
Telix has operations spanning the U.S., Europe, Japan, and other countries, and is headquartered here in Melbourne. Its Illuccix® imaging agent is already approved in multiple markets. However, both TLX101-Px and the therapy TLX101-Tx are investigational and not yet approved anywhere.
What did Telix Pharmaceuticals management say?
Dr. David N. Cade, Telix Group Chief Medical Officer, said:
We appreciate the FDA's recognition of the critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting. Our resubmission is supported by an extensive and compelling data set – particularly so for an orphan indication. We are grateful to our global clinical collaborators, who share our commitment to ensuring patients in the U.S. can benefit from this important patient management tool.
What's next for Telix Pharmaceuticals?
Telix expects the FDA review process to progress in the coming months after its resubmission. With Orphan Drug and Fast Track status, the company could potentially see an expedited pathway to approval, if the regulator is satisfied with the new data.
In the meantime, Telix continues work on its broader pipeline, including further development of both imaging and therapeutic products for cancer and rare diseases worldwide. Investors will be watching for updates on FDA timelines and any developments in the pivotal study of TLX101-Tx.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix shares have declined 59%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 10% over the same period.
